InvestSMART

EMvision Medical Devices Limited (ASX:EMV)

ALERT: Price-sensitive ASX Announcement for EMV
Current share price for EMV : $1.500 -0.205 (-12.02%)+
Announcement
Release
15 Aug 2025 9:09AM
Price at Release
$1.705
Full Release
download
Summary
EMVision Medical Devices Limited announced the successful receipt of a $3 million grant from the Medical Research Future Fund (MRFF), managed by the Australian Government Department of Health and Aged Care, to conduct a study focusing on the benefits of its portable brain imaging technology in regional and rural settings. The project, conducted in collaboration with several leading Australian hospitals and universities, will evaluate the effectiveness of EMVision’s technology for rapid stroke diagnosis and brain monitoring, particularly where access to conventional imaging is limited. The announcement underscores EMVision’s commitment to improving health outcomes in underserved regions, supporting the broader clinical adoption of its innovative device, and aligns with ongoing product development and commercialization strategies.
Key Points
  • EMVision awarded a $3 million grant from the Australian Government's MRFF.
  • Grant supports a study on the benefits of portable brain imaging in regional and rural areas.
  • Study will focus on rapid stroke diagnosis and brain monitoring.
  • Collaboration involves leading Australian hospitals and academic partners.
  • Aims to address healthcare inequities in regions with limited access to traditional imaging.
  • Supports EMVision’s clinical evidence generation and commercial readiness.
  • Reinforces company’s strategy to improve stroke care and neurological outcomes.
  • Grant provides non-dilutive funding with no requirements for matching funds.
  • EMVision is a leader in innovative, portable medical imaging technology.
  • The study’s outcome is expected to inform future clinical and commercial deployment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.